In contrast, shRNA-PKM2 xenografts showed a significant reduction in tumor size over a follow up of 100 days compared to non-silenced and mock-transfected xenografts (Fig 6C, P = 0.0146 and 0.0112, respectively). Here, PKM is linked to neoplasm.